The Effect of Antivascular Endothelial Growth Factor Therapy on the Development of Neovascular Glaucoma after Central Retinal Vein Occlusion: A Retrospective Analysis

Table 2

Ocular characteristics of ischemic and nonischemic CRVO eyes receiving anti-VEGF for macular edema.

Clinical variables	Ischemic (𝑛 = 14)	Nonischemic (𝑛 = 30)	𝑃 value
Total follow-up (mos), mean (SD)	23 (7.8)	24 (12.0)
Time between symptom onset and first dose of anti-VEGF (days), mean (SD)	25 (19.6)	43 (50.0)	0.182
Total doses of anti-VEGF, mean (SD)	5.6 (5.1)	8.4 (5.7)	0.041
Interval between doses (mos), mean (SD)	2.2 (1.8)	2.0 (0.9)	0.558
Treatment duration (mos), mean (SD)	12.1 (8.0)	18 (11.3)
Eyes with ocular NV, 𝑛 (%)	5 (35.7) See Table 3	1 (3.3) NVD
Duration from symptom onset to diagnosis of NV (mos), mean (SD)	16.7 (7.9)	9.3
Eyes receiving PRP, 𝑛 (%)	4 (28.6)	1 (3.3)
Duration from symptom onset to PRP delivery (mos), mean (SD)	12.8 (3.9)	9.3
Eyes with NVG, 𝑛 (%)	3 (21.4)	0
Duration from symptom onset to diagnosis of NVG (mos), mean (SD)	19.7 (9.9)	—
Mean initial VA	20/400	20/80
Mean final VA	20/800	20/50
Mean initial CRT (mm), mean (SD)	602 (225)	488 (221)
Mean final CRT (mm), mean (SD)	386 (254)	293 (145)